Quick Answer: Ozempic vs Wegovy
Ozempic and Wegovy contain the same active ingredient — semaglutide — but are approved for different conditions:
- Ozempic is FDA-approved for type 2 diabetes management, with a maximum dose of 2.0 mg once weekly. Weight loss is a beneficial side effect.
- Wegovy is FDA-approved specifically for chronic weight management, reaching a higher maximum dose of 2.4 mg once weekly.
If your primary goal is weight loss and you do not have diabetes, Wegovy is the purpose-built option. If you have type 2 diabetes and also want to lose weight, Ozempic may address both needs. Your prescriber can help determine the right fit.
Ozempic (Semaglutide)
Strengths
- FDA-approved for type 2 diabetes
- Significant weight loss as added benefit
- Broader insurance coverage for diabetes
- Established long-term safety data
Limitations
- Not FDA-approved for weight loss alone
- Lower maximum dose (2.0 mg vs 2.4 mg)
- Off-label use may limit coverage
Wegovy (Semaglutide)
Strengths
- FDA-approved specifically for weight loss
- Higher maximum dose (2.4 mg)
- Clinical trials designed for weight outcomes
- Cardiovascular risk reduction data (SELECT trial)
Limitations
- Higher list price than Ozempic
- Insurance coverage can be limited
- Historical supply shortages
Understanding Semaglutide: The Shared Foundation
Before comparing these two medications side by side, it helps to understand what they have in common. Both Ozempic and Wegovy are manufactured by Novo Nordisk and contain the same molecule: semaglutide. Semaglutide is a GLP-1 receptor agonist, meaning it mimics a natural hormone (glucagon-like peptide-1) that helps regulate blood sugar, slows gastric emptying, and reduces appetite.
The key difference is not the drug itself — it is the dose, the titration schedule, and the condition each is approved to treat. Think of it like the same engine in two different vehicles, each tuned for a specific purpose.
Head-to-Head Comparison
| Factor | Ozempic | Wegovy |
|---|---|---|
| Active Ingredient | Semaglutide | Semaglutide |
| FDA Indication | Type 2 diabetes | Chronic weight management |
| Maximum Dose | 2.0 mg/week | 2.4 mg/week |
| Dose Steps | 0.25 → 0.5 → 1.0 → 2.0 mg | 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg |
| Titration Period | ~8 weeks to maintenance | ~16–20 weeks to maintenance |
| Administration | Once-weekly subcutaneous injection | Once-weekly subcutaneous injection |
| Weight Loss (Clinical Trials) | ~10–15% body weight | ~12–17% body weight |
| Cardiovascular Data | SUSTAIN-6 (diabetes population) | SELECT trial (broader population) |
| List Price (Monthly, approx.) | $800–$1,000 | $1,300–$1,500 |
| Insurance Coverage | Broader (diabetes indication) | More restrictive (weight management) |
Dosing and Titration: Why It Matters
Both medications follow a gradual dose-escalation approach to minimize gastrointestinal side effects. However, their titration paths differ in meaningful ways.
Ozempic Titration Schedule
- Weeks 1–4: 0.25 mg once weekly (initiation dose)
- Weeks 5–8: 0.5 mg once weekly
- Week 9+: 1.0 mg once weekly (standard maintenance)
- Optional: 2.0 mg once weekly if additional glycemic control is needed
Wegovy Titration Schedule
- Weeks 1–4: 0.25 mg once weekly
- Weeks 5–8: 0.5 mg once weekly
- Weeks 9–12: 1.0 mg once weekly
- Weeks 13–16: 1.7 mg once weekly
- Week 17+: 2.4 mg once weekly (target maintenance)
Wegovy's longer ramp-up period reflects the higher target dose. Skipping steps or escalating too quickly can increase nausea and other GI side effects. Tracking your dose schedule carefully is essential — this is one area where a dedicated semaglutide tracking app can be especially useful.
Weight Loss: What the Clinical Evidence Shows
Because Wegovy reaches a higher maximum dose and was specifically studied for weight loss, it has generally produced stronger weight-reduction outcomes in clinical trials:
- STEP trials (Wegovy): Participants lost an average of 12–17% of their body weight over 68 weeks at the 2.4 mg dose, depending on the specific trial population.
- SUSTAIN trials (Ozempic): Participants with type 2 diabetes lost approximately 10–15% of body weight at the 1.0 mg dose, with weight loss as a secondary endpoint.
It is important to note that individual results vary significantly. Factors like baseline weight, diet, physical activity, metabolic health, and medication adherence all influence outcomes. Neither medication is a standalone solution — they work best alongside lifestyle changes.
A Note on Cardiovascular Benefits
The SELECT trial (published 2023) demonstrated that Wegovy reduced the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease — even in participants without diabetes. This was a landmark finding that expanded the clinical profile of semaglutide beyond glucose and weight management. Ozempic's cardiovascular data (SUSTAIN-6) was limited to people with type 2 diabetes.
Side Effects: What to Expect
Since both medications use the same active ingredient, their side effect profiles are nearly identical. The most frequently reported adverse effects are gastrointestinal:
Common Side Effects
- Nausea — the most commonly reported, especially during dose escalation
- Vomiting — typically decreases after the body adjusts
- Diarrhea or constipation
- Abdominal pain or bloating
- Decreased appetite — often considered a therapeutic effect
- Headache and fatigue — usually mild and transient
Managing Side Effects
- Follow the titration schedule: Do not rush dose increases
- Eat smaller, more frequent meals: Large or fatty meals may worsen nausea
- Stay hydrated: Especially important if experiencing diarrhea or vomiting
- Log your symptoms: Tracking severity and timing helps your doctor adjust treatment. Apps like Jabby make side-effect logging straightforward
Rare but serious side effects for both medications include pancreatitis, gallbladder problems, and thyroid C-cell tumors (observed in animal studies). Both carry a boxed warning about medullary thyroid carcinoma risk and are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2. Always review risks with your prescriber.
Cost and Insurance: The Practical Reality
Cost is often the deciding factor when choosing between Ozempic and Wegovy, even when the clinical choice seems clear.
List Prices (Without Insurance)
- Ozempic: Approximately $800–$1,000 per month
- Wegovy: Approximately $1,300–$1,500 per month
Insurance Coverage Differences
Ozempic generally has broader insurance coverage because type 2 diabetes is an established, widely covered indication. Wegovy coverage for weight management is improving but remains inconsistent. Many plans require prior authorization, documented BMI thresholds, or evidence of failed lifestyle interventions before approving Wegovy.
Ways to Reduce Your Costs
- Manufacturer savings cards: Novo Nordisk offers patient assistance programs for both medications
- Insurance appeals: Your doctor can submit prior authorization requests and appeal denials
- Pharmacy comparison: Prices vary across retail and mail-order pharmacies
- Employer benefit programs: Some employers are adding GLP-1 coverage as part of wellness initiatives
Who Should Choose Ozempic?
- You have been diagnosed with type 2 diabetes and want blood sugar control with weight loss as an added benefit
- Your insurance covers Ozempic but not Wegovy
- You and your doctor prefer a medication with a longer market track record
- Cost is a significant concern and Ozempic is more affordable under your plan
Who Should Choose Wegovy?
- Your primary goal is weight management and you do not have type 2 diabetes
- You want the higher maximum dose (2.4 mg) for potentially greater weight loss
- You have cardiovascular disease or risk factors and want the added CV benefit demonstrated in the SELECT trial
- Your insurance covers Wegovy or you can afford the out-of-pocket cost
Important Reminder
The choice between Ozempic and Wegovy should always be made in consultation with your healthcare provider. This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
Tracking Your Semaglutide Journey with Jabby
Whichever semaglutide medication you and your doctor choose, consistent tracking is one of the strongest predictors of long-term success. Jabby was built specifically for people on GLP-1 medications and supports both Ozempic and Wegovy with features tailored to each.
What Jabby Helps You Track
- Injection scheduling and reminders: Never miss a weekly dose
- Dose escalation management: Follow your titration timeline with automated step tracking
- Side effect logging: Record symptoms with severity and timing to share with your doctor
- Weight and body measurement trends: Visual progress charts that keep you motivated
- Injection site rotation: Interactive body map to prevent tissue irritation
- Healthcare provider reports: Generate clean summaries for your next appointment
Start Tracking Your Semaglutide Progress
Whether you're on Ozempic, Wegovy, or still deciding — Jabby gives you the tools to stay on track, manage side effects, and see your progress over time. Free to download.
Download Jabby — Free on App StoreFrequently Asked Questions
What is the difference between Ozempic and Wegovy?
Both contain semaglutide but are approved for different conditions. Ozempic is FDA-approved for type 2 diabetes management (max dose 2.0 mg weekly), while Wegovy is FDA-approved for chronic weight management (max dose 2.4 mg weekly). The higher dose in Wegovy typically leads to greater weight loss.
Can I use Ozempic instead of Wegovy for weight loss?
Some doctors prescribe Ozempic off-label for weight loss, but this is not its FDA-approved use. The maximum Ozempic dose (2.0 mg) is lower than Wegovy's target dose (2.4 mg), which may result in less weight loss. If weight management is your primary goal, discuss Wegovy with your prescriber.
Is Wegovy more expensive than Ozempic?
At list price, Wegovy is typically more expensive. However, actual out-of-pocket costs depend on your insurance plan, pharmacy, and eligibility for manufacturer savings programs. Ozempic often has broader coverage due to its diabetes indication.
Can I switch from Ozempic to Wegovy?
Yes, switching is possible under medical supervision. Because both drugs contain semaglutide, a transition usually does not require a washout period. Your doctor will determine the appropriate starting dose on Wegovy based on your current Ozempic dose.
Do Ozempic and Wegovy have the same side effects?
Yes, the side effect profiles are very similar since the active ingredient is identical. Nausea, vomiting, diarrhea, constipation, and abdominal discomfort are the most commonly reported effects with both medications, particularly during dose escalation.
How can I track my progress on semaglutide?
A dedicated tracking app like Jabby can help you log injections, monitor side effects, visualize weight trends, and prepare for doctor visits. Consistent tracking improves medication adherence and helps your healthcare team optimize your treatment plan.